



## Colorectal Cancer Screening (COL-E)

### COL-E Measure Description<sup>1</sup>

Assesses adults 50–75 who had appropriate screening for colorectal cancer with any of the following tests: annual fecal occult blood test, flexible sigmoidoscopy every 5 years, colonoscopy every 10 years, computed tomography colonography every 5 years, stool DNA test every 3 years.

### Why is COL-E Important?<sup>1</sup>

Treatment for colorectal cancer in its earliest stage can lead to a 90 percent survival rate after five years. However, more than a third of adults 50–75 do not get recommended screenings. Colorectal cancer screening of asymptomatic adults in that age group can catch polyps before they become cancerous or detect colorectal cancer in its early stages, when treatment is most effective.

### Best Practices

- ✓ Provide ongoing outreach to encourage colorectal cancer screening.
- ✓ Prepare chart to ensure that the provider orders a colorectal cancer screening at the next office visit.
- ✓ Use standing orders for colonoscopy and FOBT (Fecal Occult Blood Test).
- ✓ If patient refuses a colonoscopy, order FOBT/FIT-DNA as an alternative.
- ✓ Provide at-home FOBT colorectal cancer screening kits for use in patients' homes.

## Numerator Compliance<sup>2</sup>

Members with one or more screenings for colorectal cancer.

Any of the following meet criteria:

- Fecal occult blood test during the measurement period.
- Flexible sigmoidoscopy during the measurement period or the 4 years prior to the measurement period.
- Colonoscopy during the measurement period or the 9 years prior to the measurement period.
- CT colonography during the measurement period or the 4 years prior to the measurement period.
- Stool DNA (sDNA) with FIT test during the measurement period or the 2 years prior to the measurement period.

## Numerator Codes<sup>2</sup>

Refer to HEDIS Numerator Codes Dashboard on the Trillium HEDIS Resources website.

## Data Collection Method<sup>2</sup>

Administrative (Claims)



## Trillium Percentages/NCQA National Averages<sup>1</sup>

COL-E	Calendar Year	Trillium	NCQA National Average
Colorectal Cancer Screening Rate	2022	-	-
	2021	-	-

All summaries of the measure contained herein are reproduced with permission from HEDIS Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA)

<sup>1</sup> Source: [ncqa.org/hedis/measures](https://www.ncqa.org/hedis/measures)

<sup>2</sup> Source: HEDIS MY 2024 Tech Specs Manual Vol. 2